Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Clinical Study of Traditional Chinese Medicine in the Treatment of Phlegm-dampness Intrinsic Precocious Puberty (SHJG-PP)

4 juin 2026 mis à jour par: Children's Hospital of Fudan University

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Sanghe Jianghuo Granules in the Treatment of Girls Aged 5-8.5 Years With Precocious Puberty and Phlegm-Dampness Internal Accumulation Syndrome According to Traditional Chinese Medicine

Precocious puberty is characterized by the premature appearance of secondary sexual characteristics. Globally, the timing of puberty onset in children has shown a certain tendency to advance. In China, the incidence of precocious puberty has been increasing year by year. Precocious puberty exerts long-term and systemic impacts on children's health: advanced bone age leads to short stature; earlier sexual development than peers may induce emotional problems such as anxiety and inferiority; it may increase the risk of obesity and type 2 diabetes, posing long-term hazards to cardiovascular health; it may also result in irregular menstruation or dysmenorrhea, exerting indirect effects on reproductive health.

Modern traditional Chinese medicine (TCM) holds that: various factors lead to liver-kidney yin deficiency, hyperactivity of ministerial fire, and early arrival of tian gui (the substance responsible for promoting growth, development and reproduction), thereby triggering premature sexual development. The main syndrome types identified in clinical practice include yin deficiency with fire hyperactivity syndrome, liver stagnation transforming into fire syndrome, and phlegm-dampness internal accumulation syndrome.

Since the late 1970s, the investigators' department has taken the lead in treating precocious puberty with TCM diagnostic methods, proposing that the pathogenesis of precocious puberty lies in "kidney yin deficiency and hyperactivity of ministerial fire", and adopting the therapy of nourishing yin and purging fire for its treatment. A number of studies have confirmed that TCM medicines with the effects of nourishing yin and purging fire can effectively alleviate the yin deficiency with fire hyperactivity syndrome in children, delay the development of secondary sexual characteristics and bone age.

At present, central precocious puberty is mostly treated with gonadotropin-releasing hormone analogs (GnRHa). However, this treatment has the drawback of inhibiting the growth axis, yielding limited benefits for children with advanced bone age, overweight or obesity, and may even affect glucose and lipid metabolism. Moreover, some children with precocious puberty complicated with obesity may be intolerant to this therapy. In contrast, TCM therapy and integrated TCM-Western medicine therapy can effectively delay the development of secondary sexual characteristics and advanced bone age, and improve final adult height, thus being widely applied in China.

Although a large number of relevant studies have been reported in recent years and TCM diagnosis and treatment guidelines for precocious puberty have been formulated, there is still a lack of high-quality evidence-based medical research to support the advantageous aspects of integrated TCM-Western medicine diagnosis and treatment. Additionally, the underlying mechanisms of diagnosis and treatment for different syndrome types of precocious puberty remain insufficiently studied.

In this study, the investigators will conduct a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the effects of Sanghe Jianghuo Granules on the regulation of the hypothalamic-pituitary-gonadal (HPG) axis, metabolic homeostasis and inflammatory microenvironment, so as to verify its efficacy and safety. Furthermore, combined with transcriptomics, proteomics and network pharmacology, the investigators will identify the key targets and action pathways of Sanghe Jianghuo Granules, and verify its regulatory effect on the HPG axis through in vivo and in vitro experiments.

Aperçu de l'étude

Statut

Pas encore de recrutement

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Estimé)

200

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

  • Nom: Jian Yu, PhD
  • Numéro de téléphone: +86 13816881206
  • E-mail: yuj@shmu.edu.cn

Lieux d'étude

  • Chine
    • Fujian
      • Xiamen, Fujian, Chine
        • Xiamen Children's Hospital
        • Contact:
    • Guangdong
      • Guangzhou, Guangdong, Chine, 510405
        • The First Affiliated Hospital of Guangzhou University of Chinese Medicine
        • Contact:
    • Henan
      • Zhengzhou, Henan, Chine, 450000
        • The First Affiliated Hospital of Henan University of Chinese Medicine
        • Contact:
    • Shandong
      • Jinan, Shandong, Chine, 250011
        • Affiliated Hospital of Shandong University of TCM
        • Contact:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Chine, 210102
        • Children's Hospital of Fudan University
        • Contact:
        • Contact:
          • Wenqin Wang
          • Numéro de téléphone: +86 15001741617

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant

Accepte les volontaires sains

Non

La description

Inclusion Criteria:

  1. Female, aged between 5 and 9 years (inclusive).
  2. Presence of secondary sexual characteristics before 8 years of age, consistent with simple premature thelarche / initial central precocious puberty (CPP) / Tanner stage II.
  3. Traditional Chinese Medicine (TCM) syndrome differentiation: Phlegm-dampness internal accumulation syndrome.
  4. Body mass index (BMI) greater than the 50th percentile for same age and sex.
  5. Initial case, no prior medication for precocious puberty (including but not limited to GnRHa, sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines) within the last 3 months.
  6. Informed consent signed by the legal guardian(s), with ability to comply with the follow-up schedule.

Exclusion Criteria:

  1. Secondary precocious puberty due to central nervous system organic lesions, thyroid or adrenal disorders, ovarian tumors, or other underlying conditions.
  2. Severe hepatic or renal dysfunction, or hematological diseases.
  3. Use of sex hormones, growth hormones, Zhibai Dihuang Wan, Dabuyin Wan, or traditional Chinese weight-loss medicines within the last 3 months.
  4. Inability to cooperate with examinations or poor compliance with follow-up visits (e.g., inability to complete ultrasound, blood collection, or scheduled visits).

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Sanghe Jianghuo Granules
Participants receive Sanghe Jianghuo Granules orally, twice daily (dosage based on body weight), for 3 consecutive months. All participants also receive standardized lifestyle guidance for precocious puberty.
Médicament: Sanghe Jianghuo Granules
Composition: Mori Folium (Sang Ye), Nelumbinis Folium (He Ye), Rehmanniae Radix (Sheng Di), Anemarrhenae Rhizoma (Zhi Mu), Scutellariae Radix (Huang Qin), Atractylodis Macrocephalae Rhizoma (Bai Zhu), and other ingredients. Formulation: Granules. Administration: Oral, twice daily. Dosage: Based on body weight. Duration: 3 consecutive months.
Comparateur placebo: Placebo
Participants receive placebo (10% active-component, matching appearance, taste, and packaging of Sanghe Jianghuo Granules) orally, twice daily, for 3 consecutive months. All participants also receive standardized lifestyle guidance for precocious puberty.
Produit combiné: Placebo
10% active-component placebo, matching the appearance, taste, and packaging of Sanghe Jianghuo Granules. Administration: Oral, twice daily. Duration: 3 consecutive months.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Breast Nodule Regression Rate
Délai: Baseline (Day 0) and Week 12
Percentage reduction in breast nodule diameter at Week 12 compared to baseline, calculated as (baseline diameter - Week 12 diameter) / baseline diameter × 100%. Breast nodule diameter is measured by physical examination (palpation and/or ultrasound).
Baseline (Day 0) and Week 12

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Uterine Volume
Délai: Baseline (Day 0) and Week 12
Uterine volume measured by transabdominal ultrasound. Volume is calculated using the formula: V = (π/6) × length × anteroposterior diameter × transverse diameter, reported in cubic centimeters (cm³).
Baseline (Day 0) and Week 12
Ovarian Volume
Délai: Baseline (Day 0) and Week 12
Ovarian volume measured by transabdominal ultrasound. Volume is calculated using the formula: V = (π/6) × length × anteroposterior diameter × transverse diameter, reported in cubic centimeters (cm³).
Baseline (Day 0) and Week 12
Follicle Diameter
Délai: Baseline (Day 0) and Week 12
Maximum follicle diameter measured by transabdominal ultrasound, reported in millimeters (mm).
Baseline (Day 0) and Week 12
Serum Luteinizing Hormone (LH)
Délai: Baseline (Day 0) and Week 12
Serum LH level measured by chemiluminescent immunoassay, reported in U/L. Blood samples are collected in the morning after an overnight fast.
Baseline (Day 0) and Week 12
Serum Follicle-Stimulating Hormone (FSH)
Délai: Baseline (Day 0) and Week 12
Serum FSH level measured by chemiluminescent immunoassay, reported in U/L. Blood samples are collected in the morning after an overnight fast.
Baseline (Day 0) and Week 12
Traditional Chinese Medicine (TCM) Syndrome Score
Délai: Baseline (Day 0), Week 4, Week 8, and Week 12
TCM syndrome score assessed based on clinical evaluation of key symptoms including: preference for meat over vegetables, hyperactivity/restlessness, and greasy tongue coating. Higher scores indicate more severe syndrome manifestations.
Baseline (Day 0), Week 4, Week 8, and Week 12
Body Mass Index (BMI)
Délai: Baseline (Day 0) and Week 12
BMI calculated as weight (kg) divided by height squared (m²). Weight is measured using an electronic scale (kg, accurate to 0.1 kg). Height is measured using a mechanical height measuring device (cm, accurate to 0.1 cm).
Baseline (Day 0) and Week 12

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Children's Hospital of Fudan University

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 juillet 2026

Achèvement primaire (Estimé)

30 mars 2028

Achèvement de l'étude (Estimé)

30 juin 2028

Dates d'inscription aux études

Première soumission

4 juin 2026

Première soumission répondant aux critères de contrôle qualité

4 juin 2026

Première publication (Réel)

9 juin 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

9 juin 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

4 juin 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • fdek-tcm 2026-Q2

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner